Interesting Images18F-Fluciclovine PET/MRI in a Patient With Squamous Cell Carcinoma of the Uterine Cervix Correlated With 18F-FDG PET/CTNguyen, Nghi C. MD, PhD∗; Moon, Chan Hong PhD∗; Beriwal, Sushil MD†Author Information From the Departments of ∗Radiology †Radiation Oncology, University of Pittsburgh, Pittsburgh, PA. Received for publication March 2, 2020; revision accepted April 26, 2020. Conflicts of interest and sources of funding: This case study was sponsored by Blue Earth Diagnostics. Dr Nguyen has a scientific cooperation contract with Blue Earth Diagnostics. There is no other commercial or financial conflict of interest relevant to this article. Correspondence to: Nghi C. Nguyen, MD, PhD, UPMC Presbyterian, 200 Lothrop St, East Wing, Suite 200, Pittsburgh, PA 15213. E-mail: Nguyennc@upmc.edu. Clinical Nuclear Medicine: October 2020 - Volume 45 - Issue 10 - p 802-804 doi: 10.1097/RLU.0000000000003139 Buy Metrics Abstract A 32-year-old woman with a FIGO (International Federation of Gynecology and Obstetrics) stage IIA invasive squamous cell carcinoma of the uterine cervix underwent a clinical FDG PET/CT scan, which revealed intense uptake in the primary. On research 18F-fluciclovine PET/MRI, the primary showed elevated fluciclovine uptake at 5 and 40 minutes after radiotracer injection, with no evidence of regional or distant metastasis. Fluciclovine PET may have diagnostic value for cervical cancer imaging with a potential advantage over FDG of minimal urinary activity from renal excretion; however, in this patient, the metabolic activity was inferior to that of FDG PET. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.